In addition to my prior post further highlights from the B Vaxx...

In addition to my prior post further highlights from the B Vaxx trial document include the following excerpts,

(note for those that are unsure what  Trastuzumab is it is the product which Genentech sells sold under the brand name Herceptin) I

Patient vaccine antibodies cause enhanced antiproliferative effects The effects of the patient antibodies were tested using BT-474 in the presence of native HER-2 ligand, heregulin (HRG). Figure 5A shows that each of the patient sera in Cohort 2 was able to inhibit proliferation of the HER-2 overexpressing cells BT-474 as compared to pre-immune sera. The level of inhibition was comparable to trastuzumab, suggesting that our vaccine antibodies were equally effective.

and 

Patient antibodies induce apoptosis Targeting apoptotic regulatory pathways in cancer is a promising strategy for therapeutic agents. We next evaluated whether patients’ vaccine antibodies following vaccination were capable of inducing apoptosis of cancer cells by caspase activity assay. Using breast cancer cells BT-474 treated with the patient antibodies as inhibitors, we found that each of the patient antibodies (3Y+4; 4 weeks post third vaccine) demonstrated significant increases in the amount of caspase 3 and 7 activity in treated cells as compared to the negative controls (pre-immune sera) (Figure 5C). Vaccine antibodies increased caspase release more than 100-fold, increased cell death similar to trastuzumab.

Overall this is looking very good, I wouldn't be surprised if at the moment  IMU and Genentech Roche are not sitting down negotiating a licencing agreement to  use B Vaxx for patients whom may have a reaction to trastuzumab (Herceptin) or just switch to B-Vaxx and then  should Her-Vaxx turn out to be even more superior compared to the B Vaxx ( which many expect it will be ) then Genentech  might be offered the ability to upgrade their licence ( at a fee ) to Her Vaxx at a latter date.

at the end of the day we can only speculate, but to me the science and opportunity are looking better and better with each new announcement.

all the best to all holders 
fp